lower total revenu kevzara
lower top-line optic neg ep unchang
expect share trade margin follow detail provid
previous announc sanofi partnership restructur biggest chang view
lower total revenu go forward repres
revenu dupix kevzara praluent
chang decreas total revenu opex
estim respect impact net
incom ep expect y/i guidanc provid
expect addit detail earn call may despit
new cleaner report methodolog lower top-line number potenti
volatil sale due could pressur stock view updat
estim base new account reiter neutral rate po
kevzara notabl miss updat
restructur kevzara still final expect result
outsiz benefit sanofi anticip gain sole global right sanofi indic
delay due newfound potenti treatment initi data phase
us studi expect end april result restructur regeneron
begin record us praluent sale royalti ou praluent sale mid-
singl digit partnership agreement dupix far highest
gross product jv portfolio expect remain unchang
account chang go effect start
larg portion revenu recogn sanofi jv
total jv revenu previous reimburs regeneron sg
expens sanofi move forward reimburs net within
expens line item incom statement up-front payment develop
mileston also move total revenu new oper incom
expens line item chang reflect oper incom
break major chang impact estim page
full definit iqmethod sm measur see page
bofa secur seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
biopharmaceut
compani focus develop
therapeut human antibodi treatment
inflamm diseas regeneron
product sale driven princip vegf
inhibitor eylea approv use wet
age-rel macular degener wet
diabet macular edema dme dupix
treatment atop dermat asthma
give neutral rate base fade
eylea revenu off-set sanofi joint ventur profit
growth driven dupix libtayo add margin
outlook earli pipelin offer
long-term upsid yet unproven
total option expens
total option expens
total option expens
incom loss tax non gaap
project impact incom statement
exhibit chang histor estim base updat account methodolog
highlight row repres item impact account chang
look ahead earn
analysi consum prescript trend follow outbreak
indic decreas start new medicin requir physician visit
reduct high touch treatment requir in-offic administr non-lif
threaten diseas view could signal weaker expect eylea sale
patient receiv intravitr inject silver line
weak beovu launch compet therapi novarti see view
therefor see regeneron one highli expos name coverag
thought estim impact could felt
potenti signal depend durat outbreak increas
off-label kevzara use sever patient may benefit sale slightli howev
weak dupix would off-set benefit within sanofi jv
price object base probability-adjust net present valu npv
analysi eylea includ ou revenu bayer collabor
sanofi collabor revenu includ dupix product revenu
libtayo earli pipelin asset well
approxim net cash use wacc rang approv
product pipelin product termin growth eylea earli
downsid risk price object slower-than-expect growth product
sale particularli eylea dupix failur obtain approv addit
indic dupix pipelin setback
upsid risk price object better expect eylea growth trajectori
larger contribut dupix regeneron top-line commerci uptak
new indic better expect econom realiz regeneron
geoff meacham herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
compani
qualiti earn
iqmethod smi set bofa global research standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa global research
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
